BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch

Q3 2025 Management View Jay Short, Co-Founder, CEO & Chairman, emphasized that BioAtla is "currently in advanced stages to ...
The Manila Times

Faraday Future Reports Financial Results for Q3 2025

FX Super One has entered the pre-production phase at its Hanford manufacturing factory with the target of the first FX Super ...